Long non-coding RNA SNHG5 promotes the osteogenic differentiation of bone marrow mesenchymal stem cells via the miR-212-3p/GDF5/SMAD pathway.
GDF5
Osteogenesis
SNHG5
YY1
miR-212-3p
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
28 03 2022
28 03 2022
Historique:
received:
29
06
2021
accepted:
23
08
2021
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
5
4
2022
Statut:
epublish
Résumé
The treatment of bone loss has posed a challenge to clinicians for decades. Thus, it is of great significance to identify more effective methods for bone regeneration. However, the role and mechanisms of long non-coding RNA small nucleolar RNA host gene 5 (SNHG5) during osteogenic differentiation remain unclear. We investigated the function of SNHG5, Yin Yang 1 (YY1), miR-212-3p and growth differentiation factor 5 (GDF5) in osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) in vitro and in vivo. Molecular mechanisms were clarified by chromatin immunoprecipitation assay and dual luciferase reporter assay. We found SNHG5 expression was upregulated during osteogenesis of hBMSCs. Knockdown of SNHG5 in hBMSCs inhibited osteogenic differentiation while overexpression of SNHG5 promoted osteogenesis. Moreover, YY1 transcription factor directly bound to the promoter region of SNHG5 and regulated SNHG5 expression to promote osteogenesis. Dual luciferase reporter assay confirmed that SNHG5 acted as a miR-212-3p sponge and miR-212-3p directly targeted GDF5 and further activated Smad1/5/8 phosphorylation. miR-212-3p inhibited osteogenic differentiation, while GDF5 promoted osteogenic differentiation of hBMSCs. In addition, calvarial defect experiments showed knockdown of SNHG5 and GDF5 inhibited new bone formation in vivo. Our results demonstrated that the novel pathway YY1/SNHG5/miR-212-3p/GDF5/Smad regulates osteogenic differentiation of hBMSCs and may serve as a potential target for the treatment of bone loss.
Sections du résumé
BACKGROUND
The treatment of bone loss has posed a challenge to clinicians for decades. Thus, it is of great significance to identify more effective methods for bone regeneration. However, the role and mechanisms of long non-coding RNA small nucleolar RNA host gene 5 (SNHG5) during osteogenic differentiation remain unclear.
METHODS
We investigated the function of SNHG5, Yin Yang 1 (YY1), miR-212-3p and growth differentiation factor 5 (GDF5) in osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) in vitro and in vivo. Molecular mechanisms were clarified by chromatin immunoprecipitation assay and dual luciferase reporter assay.
RESULTS
We found SNHG5 expression was upregulated during osteogenesis of hBMSCs. Knockdown of SNHG5 in hBMSCs inhibited osteogenic differentiation while overexpression of SNHG5 promoted osteogenesis. Moreover, YY1 transcription factor directly bound to the promoter region of SNHG5 and regulated SNHG5 expression to promote osteogenesis. Dual luciferase reporter assay confirmed that SNHG5 acted as a miR-212-3p sponge and miR-212-3p directly targeted GDF5 and further activated Smad1/5/8 phosphorylation. miR-212-3p inhibited osteogenic differentiation, while GDF5 promoted osteogenic differentiation of hBMSCs. In addition, calvarial defect experiments showed knockdown of SNHG5 and GDF5 inhibited new bone formation in vivo.
CONCLUSION
Our results demonstrated that the novel pathway YY1/SNHG5/miR-212-3p/GDF5/Smad regulates osteogenic differentiation of hBMSCs and may serve as a potential target for the treatment of bone loss.
Identifiants
pubmed: 35346361
doi: 10.1186/s13287-022-02781-8
pii: 10.1186/s13287-022-02781-8
pmc: PMC8962127
doi:
Substances chimiques
GDF5 protein, human
0
Growth Differentiation Factor 5
0
MIRN212 microRNA, human
0
MicroRNAs
0
RNA, Long Noncoding
0
long non-coding RNA SNHG5, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Informations de copyright
© 2022. The Author(s).
Références
J Biosci. 2020;45:
pubmed: 32713855
Aging (Albany NY). 2020 May 20;12(11):10527-10543
pubmed: 32434960
Cancer Biother Radiopharm. 2019 Nov;34(9):589-596
pubmed: 31657621
Nat Med. 2012 Feb 05;18(3):456-62
pubmed: 22306732
Tissue Cell. 2020 Dec;67:101429
pubmed: 32861877
Eur Rev Med Pharmacol Sci. 2020 Jan;24(1):18-28
pubmed: 31957814
Int J Mol Sci. 2016 Aug 20;17(8):
pubmed: 27556448
J Biol Regul Homeost Agents. 2021 Apr 30;35(2):605-615
pubmed: 33928771
J Cell Biochem. 2018 Nov;119(11):9462-9473
pubmed: 30010216
Genome Biol. 2015 Jan 05;16:2
pubmed: 25601191
Lab Invest. 2021 Mar;101(3):341-352
pubmed: 33318617
Biol Chem. 2006 Apr;387(4):451-60
pubmed: 16606344
Stem Cell Reports. 2017 Mar 14;8(3):773-786
pubmed: 28262546
Am J Cancer Res. 2018 Mar 01;8(3):514-525
pubmed: 29637005
Cancer Cell Int. 2018 Sep 18;18:141
pubmed: 30250399
Int J Biol Macromol. 2019 Feb 1;122:1046-1052
pubmed: 30227213
Curr Gene Ther. 2021;21(1):81-88
pubmed: 33019931
Cell. 2003 Jun 13;113(6):685-700
pubmed: 12809600
Stem Cells. 2015 Dec;33(12):3481-92
pubmed: 26417995
Int J Cancer. 2014 Nov 15;135(10):2282-93
pubmed: 24343426
Exp Mol Pathol. 2020 Apr;113:104366
pubmed: 31891679
J Cell Physiol. 2020 Oct 28;:
pubmed: 33111341
Int J Mol Med. 2018 Feb;41(2):669-678
pubmed: 29207050
Nat Commun. 2016 Dec 22;7:13875
pubmed: 28004750
Curr Stem Cell Res Ther. 2020;15(3):243-249
pubmed: 31880266
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
Stem Cell Res Ther. 2020 Jan 3;11(1):5
pubmed: 31900200
Stem Cell Res Ther. 2018 Aug 31;9(1):232
pubmed: 30170617
J Mol Biol. 2005 Jun 24;349(5):933-47
pubmed: 15890363
Development. 2000 Feb;127(3):605-19
pubmed: 10631181
J Inflamm Res. 2020 Sep 30;13:635-646
pubmed: 33061528
Oral Dis. 2021 Jul;27(5):1268-1282
pubmed: 32890413
Cell Death Dis. 2020 Jul 30;11(7):601
pubmed: 32732881
Cell Biol Int. 2017 Jul;41(7):779-786
pubmed: 28460412
J Gene Med. 2021 Mar;23(3):e3296
pubmed: 33179372
Nat Struct Mol Biol. 2010 Oct;17(10):1169-74
pubmed: 20924405
Cell Tissue Res. 2021 Feb;383(2):723-733
pubmed: 32960357
Front Oncol. 2019 Nov 20;9:1230
pubmed: 31824839
Theranostics. 2018 Sep 09;8(17):4733-4749
pubmed: 30279734
Int J Biol Macromol. 2021 Apr 30;177:317-327
pubmed: 33621568
Curr Pharm Des. 2013;19(19):3364-73
pubmed: 23432680